Overview - Investors & Press - T2biosystems
T2Biosystems     Print Page | Close Window

Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.19
Change (%) Stock is Up 0.15 (2.98%)
Volume311,120
Data as of 04/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/24/17T2 Biosystems Announces 2017 First Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments. Interested parties may access the live call v... 
Printer Friendly Version
04/19/17T2 Biosystems to Host Symposium at 27th European Congress of Clinical Microbiology and Infectious Diseases
Speakers to review clinical and economic benefits of direct-from-whole-blood identification of sepsis pathogens LEXINGTON, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that the company will be hosting a special symposium highlighting the clinical and economic benefits of testing with the T2Candida® Panel and previewing the performance of the T2Bacteria™ Panel at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) ... 
Printer Friendly Version
03/28/17T2 Biosystems to Present at the Needham Healthcare Conference
LEXINGTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to attend and present at the Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20am ET at the Westin New York Grand Central Hotel in New York City. A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company’s website at www.t2biosyste... 
Printer Friendly Version
02/13/17T2 Biosystems Reports Fourth Quarter and Full-Year 2016 Results
LEXINGTON, Mass., Feb. 13, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, today announced operating highlights and financial results for the fourth quarter and year ended December 31, 2016. Recent Operational and Fourth Quarter Performance Highlights: Secured commitments in the fourth quarter that will provide access to an estimated... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Tucker Elcock, Teneo Strategy Tucker.Elcock@teneostrategy.com
(212) 886-9319

Data provided by Nasdaq. Minimum 15 minutes delayed.